IRulya Therapeutics Inc.
Research IRulya Therapeutics Inc. (IRLA) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerIRLA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 75.49M
- Free cash flow-USD 18.89M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 83.98M | -USD 41.78M | n/a | -336 | USD 5.81M | USD 18.03M | -USD 35.71M |
| FY2024 | USD 0 | -USD 56.83M | -USD 32.16M | n/a | -262 | USD 6.21M | USD 14.32M | USD 30.15M |
| FY2023 | USD 0 | -USD 31.39M | -USD 18.45M | n/a | -168 | USD 20.75M | USD 13.43M | USD 85.08M |
| FY2022 | USD 0 | -USD 51.66M | -USD 44.17M | n/a | -308 | USD 40.59M | USD 0 | USD 100.59M |
About IRulya Therapeutics Inc.
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does IRulya Therapeutics Inc. do?
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.